Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ethosuximide dosage regimens

R A Buchanan, A W Kinkel, J L Turner

    Clinical Pharmacology and Therapeutics
    |February 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Altered synaptic glutamate homeostasis contributes to cognitive decline in young APP/PSEN1 mice.

    Neurobiology of disease·2021
    Same author

    Nanosecond X-Ray Photon Correlation Spectroscopy on Magnetic Skyrmions.

    Physical review letters·2017
    Same author

    Highly efficient star formation in NGC 5253 possibly from stream-fed accretion.

    Nature·2015
    Same author

    Observation of deflection of a beam of multi-GeV electrons by a thin crystal.

    Physical review letters·2015
    Same author

    Demonstration of single-crystal self-seeded two-color x-ray free-electron lasers.

    Physical review letters·2015
    Same author

    Effects of oxytocin, lipopolysaccharide (LPS), and polyunsaturated fatty acids on prostaglandin secretion and gene expression in equine endometrial explant cultures.

    Domestic animal endocrinology·2012
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Single daily ethosuximide (ethosuximide) is effective for treating petit mal epilepsy. This dosing regimen offers convenience and may improve patient compliance without compromising therapeutic plasma levels.

    Area of Science:

    • Pediatric Neurology
    • Clinical Pharmacology

    Background:

    • Petit mal epilepsy is a common form of childhood epilepsy.
    • Ethosuximide is a first-line antiepileptic drug for absence seizures.
    • Optimizing dosing regimens can improve treatment outcomes and patient adherence.

    Purpose of the Study:

    • To compare plasma ethosuximide levels and clinical efficacy between divided daily and single daily administration in children with petit mal epilepsy.
    • To evaluate the safety and tolerability of different ethosuximide dosing schedules.

    Main Methods:

    • A crossover study design was used in 9 children with petit mal epilepsy.
    • Children received their established ethosuximide dose in divided doses for 4 weeks, single morning doses for 4 weeks, and divided doses again for 4 weeks.

    Related Experiment Videos

  • Plasma drug levels, seizure frequency, and adverse events were monitored throughout the study.

    • Main Results:

    • No significant difference in seizure frequency (petit mal or grand mal) was observed between dosing regimens.
    • Plasma ethosuximide levels peaked faster and declined quicker with single daily dosing but remained within the therapeutic range.
    • The mean elimination half-life of ethosuximide was 29 hours; no adverse experiences were reported.

    Conclusions:

    • Single daily administration of ethosuximide is clinically effective for managing petit mal epilepsy in children.
    • This simplified dosing schedule may enhance convenience and improve patient compliance.
    • Further investigation is warranted to understand the observed lower plasma levels during the second divided dose period.